• 1
    Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 15921609.
  • 2
    Fan JG, Jia JD, Li YM et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. (published in Chinese on Chinese Journal of Hepatology 2010; 18:163–166). J. Dig. Dis. 2011; 12: 3844.
  • 3
    Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 2009; 50: 204210.
  • 4
    Carvalhana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care 2012; 15: 468473.
  • 5
    Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2012; 46: 457467.
  • 6
    McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J. Acad. Nutr. Diet. 2012; 112: 401409.
  • 7
    de Wit NJ, Afman LA, Mensink M, Müller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J. Hepatol. 2012; 57: 13701373.
  • 8
    Strychar I. Diet in the management of weight loss. CMAJ 2006; 174: 5663.
  • 9
    Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Engl. J. Med. 2009; 360: 859873.
  • 10
    Moyer VA; U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012; 157: 373378.
  • 11
    Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J. Hepatol. 2012; 56: 255266.
  • 12
    Maersk M, Belza A, Stodkilde-Jorgensen H et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am. J. Clin. Nutr. 2012; 95: 283289.
  • 13
    Abdelmalek MF, Suzuki A, Guy C et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 19611971.
  • 14
    Stanhope KL, Schwarz JM, Keim NL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Invest. 2009; 119: 13221334.
  • 15
    Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2012; 23: 203208.
  • 16
    Ferolla SM, Ferrari TC, Lima ML et al. Dietary patterns in Brazilian patients with nonalcoholic fatty liver disease: a cross-sectional study. Clinics (Sao Paulo) 2013; 68: 1117.
  • 17
    Savard C, Tartaglione EV, Kuver R et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013; 57: 8192.
  • 18
    Min HK, Kapoor A, Fuchs M et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012; 15: 665674.
  • 19
    Parker HM, Johnson NA, Burdon CA et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 2012; 56: 944951.
  • 20
    Santoro N, Savoye M, Kim G et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS ONE 2012; 7: e37827.
  • 21
    Bjermo H, Iggman D, Kullberg J et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am. J. Clin. Nutr. 2012; 95: 10031012.
  • 22
    Bortolotti M, Kreis R, Debard C et al. High protein intake reduces intrahepatocellular lipid deposition in humans. Am. J. Clin. Nutr. 2009; 90: 10021010.
  • 23
    Bortolotti M, Maiolo E, Corazza M et al. Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients. Clin. Nutr. 2011; 30: 494498.
  • 24
    Tovar AR, Torres N. The role of dietary protein on lipotoxicity. Biochim. Biophys. Acta 2010; 1801: 367371.
  • 25
    Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr. Opin. Gastroenterol. 2012; 28: 159165.
  • 26
    Masterjohn C, Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr. Rev. 2012; 70: 4156.
  • 27
    Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2012; 35: 7682.
  • 28
    Molloy JW, Calcagno CJ, Williams CD et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55: 429436.
  • 29
    Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885904.
  • 30
    Rodríguez-Hernández H, Cervantes-Huerta M, Rodríguez-Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Ann. Hepatol. 2011; 10: 486492.
  • 31
    Grønbæk H, Lange A, Birkebæk NH et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J. Pediatr. Gastroenterol. Nutr. 2012; 54: 223228.
  • 32
    Sevastianova K, Santos A, Kotronen A et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am. J. Clin. Nutr. 2012; 96: 727734.
  • 33
    Goran MI, Walker R, Allayee H. Genetic-related and carbohydrate-related factors affecting liver fat accumulation. Curr. Opin. Clin. Nutr. Metab. Care 2012; 15: 392396.
  • 34
    Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care 2012; 15: 374380.
  • 35
    Nobili V, Bedogni G, Alisi A et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch. Dis. Child. 2011; 96: 350353.
  • 36
    Oliveira LP, de Jesus RP, Boulhosa RS et al. Effect of soy protein supplementation in patients with chronic hepatitis C: a randomized clinical trial. World J. Gastroenterol. 2012; 18: 22032211.
  • 37
    Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012; 32: 701711.
  • 38
    Dunn W, Sanyal AJ, Brunt EM et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 2012; 57: 384391.
  • 39
    Lavine JE, Schwimmer JB, Van Natta ML et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 16591668.
  • 40
    Klein EA, Thompson IM Jr, Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 15491556.
  • 41
    Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 2011; 22: 699711.
  • 42
    Aller R, De Luis DA, Izaola O et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2011; 15: 10901095.
  • 43
    Malaguarnera M, Vacante M, Antic T et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012; 57: 545553.